Gracell Biotechnologies Investor Relations Material
Latest events
Q3 2023
Gracell Biotechnologies
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Gracell Biotechnologies Inc
Access all reports
Gracell Biotechnologies Inc. (GRCL) is a clinical-stage biopharmaceutical company primarily focused on discovering and developing innovative cell therapies for cancer treatment. The company leverages its proprietary FasTCAR and TruUCAR technology platforms, along with its SMART CART™ technology module, to develop therapies designed to offer fast, deep, and durable responses for patients suffering from cancer and autoimmune diseases. Gracell Biotechnologies is headquartered in Suzhou, China, and its shares are listed on the Nasdaq.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
GRCL
Country
🇺🇸 United States